Late restoration of renal function in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation
- PMID: 29679168
- DOI: 10.1007/s10067-018-4100-8
Late restoration of renal function in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation
Abstract
In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), many patients with severe renal dysfunction are on dialysis at presentation. Among those who got rid of dialysis finally, renal restoration happened mostly within the first 3 months of treatment. However, in clinical practice, we occasionally encountered patients who got rid of dialysis after 3 months. The current study investigated clinical and pathological features of AAV patients with so-called delayed renal function restoration. A total of 156 patients with ANCA-associated glomerulonephritis who were on dialysis at presentation were retrospectively recruited. Clinical and pathological data as well as treatment and outcomes were analyzed. Among these 156 patients, 58 and 12 patients got rid of dialysis within and after 3 months, respectively. Among the 12 patients with delayed renal function restoration, 8 and 4 patients got rid of dialysis within and after 6 months, respectively. Among the 72 patients who were still on dialysis at the end of 3 months since the initiation of immunosuppressive therapy, those receiving intravenous cyclophosphamide therapy over 3 months had significantly higher proportion of renal function restoration than those receiving intravenous cyclophosphamide for only 3 months (8/14 versus 4/58, P < 0.001). For patients with ANCA-associated glomerulonephritis who were on dialysis at presentation, there is an unnegligible proportion of patients who had their renal function restoration beyond 3 months since the initiation of immunosuppressive therapy. Further studies are needed to investigate whether, and for whom, cyclophosphamide prescription should be prolonged for more than 3 months.
Keywords: ANCA; Dialysis-dependent; Glomerulonephritis; Renal restoration; Vasculitis.
Similar articles
-
Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center.Semin Arthritis Rheum. 2013 Apr;42(5):515-21. doi: 10.1016/j.semarthrit.2012.09.005. Epub 2013 Jan 16. Semin Arthritis Rheum. 2013. PMID: 23332902
-
ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.BMC Nephrol. 2015 Jun 30;16:90. doi: 10.1186/s12882-015-0091-8. BMC Nephrol. 2015. PMID: 26123651 Free PMC article.
-
ANCA-associated vasculitis in scleroderma: A renal perspective .Clin Nephrol. 2018 Dec;90(6):413-418. doi: 10.5414/CN109445. Clin Nephrol. 2018. PMID: 30106367
-
[ANCA-associated vasculitides: what nephrologists need to know].Nephrol Ther. 2024 Dec 1;20(7):666-673. doi: 10.1684/ndt.2024.100. Nephrol Ther. 2024. PMID: 39917792 Review. French.
-
[Focal segmental glomerulosclerosis after renal transplantation in a child with ANCA-associated glomerulonephritis: case report and literature review].Zhonghua Er Ke Za Zhi. 2016 Dec 2;54(12):936-940. doi: 10.3760/cma.j.issn.0578-1310.2016.12.013. Zhonghua Er Ke Za Zhi. 2016. PMID: 27938596 Review. Chinese.
Cited by
-
Pathological severity determines the renal recovery for anti-myeloperoxidase antibody-associated vasculitis requiring dialysis at disease onset: a retrospective study.BMC Nephrol. 2019 Jul 30;20(1):287. doi: 10.1186/s12882-019-1487-7. BMC Nephrol. 2019. PMID: 31362703 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical